Great, thank you.
Sorry Claudia Welcome for earnings quarter that to and good morning everyone. call and disruption. Thank update. you first corporate XXXX the
a certainly year States, for Solutions. challenge for United world, been the has for and the This CHF
the and rest than that the is less device but uncertainty of of small very we pleased are impacted medical We year companies, optimism. are full many
durability changed dramatically remain has business for in run and long changed world time being, the about has really model Although we not know optimistic our the the our the we business. of
We our are and are that focused. confident clear priorities
of safety be will Solutions CHF term, nearest focused our the employees. the on In health and
rest at is and remotely. our working manufacturing our to Our by the business of maintaining facility production work staff onsite continues team operations
impact we Also, human remain do resources, strive as and While optimal control to than our manage use we to translate will support to all this of value shareholder the continue they the the capital to storm critical weathering medium the ensuring less to term. may pandemic. COVID-XX customers and of in into can will longer
we future, the for expense uncertainty of level and operations. managing avenues are our closely fund controls, to implementing cash, considerable pursuing a With
by COVID-XX we several been the have to XX and many Aquadex nurses consoles provided loaners providing over and on system. in weeks, able have as physicians hotspots. battle hospitals, help We remote hospitals the consoles to the six Aquadex COVID-XX training In pandemic past the
We have established training remote web protocols tools and webinars. using video
using We and via closely system. helping have telephone, survive worked tools with physicians the successfully emails patients who text, key web are Aquadex virus the
patients’ how also COVID-XX ways offloaded acute on they have peers their experience as have supplemented dialysis these the fluid kidneys on We patients need in they help and finding managed removing by they failure. patients’ physicians many stress so have educate for the their are lungs, excess successfully fluid, how to how kidney
the and materials. Aquadex supply components and have minimal for seen of products the we chain continues of Production disruption
raise were When to for we on if uncertain uncertain equity Administration’s from would the growth to Payroll and we we were were Small treatment our due to workforce. to of restrictions were uncertain Protection ability our we able were patients if applied with We help our in the Business elective continue maintain actually way. markets able We we a if of the uncertain money maintain be sales we the Program, COVID procedures. meaningful could to
of equity additional became the to XX raise have and help physicians we rate increase to markets. COVID-XX volumes from an SmartFlow treat our patients. important been the sales been As able needed as capital console new of the past maintain Aquadex days to have to therapy we unfolded, Aquadex production small amounts have our the We systems to able
this Payroll allowing from Although including we be and about survive we to Protection help there of the be $X.XX the to this lot decided the funds time, a have all employees, employees we optimistic uncertainty business field of will able remain we our to return At these is the still Program, another retain SBA our future, small time. organization. million during believe to received used in XX sales
from rules. procedures. in XXX% hospitals with this the most close and sales them six due great cost and enormous four a These hospital Before elective employees in to future of restricted required what the these recruiting came of considered team and access furlough new expense, almost from field challenges with to our XX new now replacing face of COVID-XX pandemic, clinical XX% to hospitals business cost with from been costs, would become have to the training not-too-distant to territory months to The high be proficient. time the are
running. elective will and As needed the sales hospitals the and to online procedures, hit back be clinical start come procedures our to schedule ground again team elective ready
Two-thirds of COVID-XX pandemic. the the impact to prior overall in the books was the quarter first of
for we included four release and the First quarter the in In was April. we applications an product January, in clearance excellent SmartFlow market for in issued and and expanded in on enhancements Aquadex patent was received the Mark distribution the new market weighing to February, clearance Switzerland, and over console press console. our additional of international foundational regulatory patent Aquadex for business. use XX CE children FDA filing India. Accomplishments for of one XXXK Aquadex We a Germany, quarter received new for pediatrics kilograms, filed Aquadex SmartFlow we the market received in to Austria clearance
in if March, sponsored in Dr. doubled use York materials launched COVID-XX Kazory for volume increase Georgia. ordered in required. of by COVID-XX of the the children’s raw management Aquadex and New in We patients. webinar We and treatment further a hospitals In strategy to We’ve hotspots Amir supported our moderated pediatrics. using production to of on Aquadex production SmartFlow we new our marketing initiation consoles Aquadex
over strong year. was quarter Revenue $X.X a increase million, the a representing for increase and at XX.X% XX.X% quarter prior over prior
our QX you through turn over Claudia, who to now XXXX the call financial walk and will will I details. results
to call Following some open that, additional I will and the provide questions. will comments
